ABBVIE INC. (ABBV) Valuation
Historical valuation analysis based on 1280 data points (2021-09-13 to 2026-10-16)
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 20...
ABBVIE INC. (ABBV) currently trades at a P/E ratio of 79.93 (historical range: 17.79–181.34, median: 48.19), placing it at the 79th percentile — above its historical average, P/S ratio of 7.83 (range: 3.46–7.83, 100th percentile — expensive relative to its history), EV/EBITDA of 33.71 (range: 15.21–54.65, 80th percentile).
Over the historical period (2021-09-13 to 2026-10-16), ABBVIE INC.'s P/E ratio has expanded by 213% over the observed period (from an average of 29.5 to 92.3).
ABBVIE INC. trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 79.93 | 48.19 | 79th | above its historical average |
| P/S Ratio | 7.83 | 5.39 | 100th | expensive relative to its history |
| EV/EBITDA | 33.71 | 25.04 | 80th | expensive relative to its history |
| FCF Yield | 3.61% | 7.58% | 0th | expensive relative to its history |
ABBVIE INC. (ABBV) Valuation & P/E History
ABBVIE INC. (ABBV) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry currently trading at $285.95 with a market capitalization of $505.3 billion. This page provides historical valuation analysis for ABBV based on 1280 data points covering 2021-09-13 to 2026-10-16. The P/E ratio of 79.93 is above the historical median of 48.19, placing ABBV at the 79th percentile of its valuation range. The P/S ratio of 7.83 compares to a median of 5.39.
ABBV Valuation Metrics & Historical Range
The valuation table above shows ABBVIE INC.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether ABBV is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests ABBV is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for ABBVIE INC..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is ABBV Overvalued or Undervalued?
ABBVIE INC. trades well above its own historical valuation range across most metrics. The overall valuation percentile of 86 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive ABBV is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full ABBV analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.ABBV trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.